Nuvation Bio’s Taletrectinib Clears Key UK Regulatory Milestone for ROS1+ Lung Cancer June 29, 2026 by Mathieu Maurice Nuvation Bio, a global oncology company dedicated to addressing some of the most challenging areas in cancer care, has announced that the U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA) …
